drugset / Trial / NCT06611033

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

NCT06611033

Phase 1 Completed 65 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindBasic science

Summary

The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.

Timeline

Start
2024-09-25
Primary completion
2026-01-09
Completion
2026-01-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator PCV20 Vaccine Intramuscular
Subject V118 Unknown Intramuscular
Subject V118C Vaccine Intramuscular

Indications

No indication recorded.